Literature DB >> 15829916

Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat-a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage.

Frank Richter1, Oskar Mikulik, Andrea Ebersberger, Hans-Georg Schaible.   

Abstract

Cortical spreading depression (CSD) is thought to be a neuronal mechanism that expands the penumbra zone after focal brain ischemia and that causes migraine aura. Both adrenergic agonists and antagonists significantly influence the size of the penumbra zone and decline the frequency of migraine. To study whether these compounds act by influencing CSD, we applied different drugs topically to an area of the exposed cortex of anesthetized adult rats and observed the migration of CSD-related DC potential deflections across the treated area. The adrenergic agonist norepinephrine (1 mmol/L) and the alpha(2)-agonist clonidine (0.56 mmol/L) blocked reversibly the migration of CSD. The beta-blocker propranolol (250 micromol/L to 1 mmol/L) dose-dependently diminished migration velocity or even blocked migration of CSD. The CSD blockade by the alpha(2)-antagonist yohimbine (1.75 mmol/L) was because of its action on inhibitory 5-HT(1A) receptors. None of the substances in the concentrations used had influence on regional cerebral blood flow or on systemic arterial blood pressure. The data suggest that the interference of these compounds with CSD may contribute to their beneficial therapeutic effect. The effect of beta-receptor antagonists in human migraine needs further exploration, since these drugs also work in migraine without aura.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15829916     DOI: 10.1038/sj.jcbfm.9600120

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  18 in total

1.  Is migraine a lateralization defect?

Authors:  Jani Kaaro; Timo Partonen; Paulami Naik; Nouchine Hadjikhani
Journal:  Neuroreport       Date:  2008-08-27       Impact factor: 1.837

Review 2.  Central mechanism of action of antimigraine prophylactic drugs.

Authors:  Gerardo Casucci; Veronica Villani; Fabio Frediani
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

Review 3.  Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action.

Authors:  Till Sprenger; M Viana; C Tassorelli
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

4.  Systematic review of the pharmacological agents that have been tested against spreading depolarizations.

Authors:  Anna Klass; Renan Sánchez-Porras; Edgar Santos
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-20       Impact factor: 6.200

5.  Modulation of brainstem activity and connectivity by respiratory-gated auricular vagal afferent nerve stimulation in migraine patients.

Authors:  Ronald G Garcia; Richard L Lin; Jeungchan Lee; Jieun Kim; Riccardo Barbieri; Roberta Sclocco; Ajay D Wasan; Robert R Edwards; Bruce R Rosen; Nouchine Hadjikhani; Vitaly Napadow
Journal:  Pain       Date:  2017-08       Impact factor: 6.961

6.  Genetic TPH2 variants and the susceptibility for migraine: association of a TPH2 haplotype with migraine without aura.

Authors:  Alexander Jung; Andreas Huge; Gregor Kuhlenbäumer; Steffi Kempt; Tanja Seehafer; Stefan Evers; Klaus Berger; Martin Marziniak
Journal:  J Neural Transm (Vienna)       Date:  2010-08-26       Impact factor: 3.575

Review 7.  [Headache. Current status of research and treatment].

Authors:  A Straube; C Gaul
Journal:  Schmerz       Date:  2015-10       Impact factor: 1.107

8.  Efficacy profile of noninvasive vagus nerve stimulation on cortical spreading depression susceptibility and the tissue response in a rat model.

Authors:  Tzu-Ting Liu; Andreia Morais; Cenk Ayata; Jiin-Cherng Yen; Tsubasa Takizawa; Inge Mulder; Bruce J Simon; Shih-Pin Chen; Shuu-Jiun Wang
Journal:  J Headache Pain       Date:  2022-01-21       Impact factor: 7.277

9.  Patient outcome in migraine prophylaxis: the role of psychopharmacological agents.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Giulia Serra; Giovanni Dominici; Juliana Fortes-Lindau; Monica Pastina; Ludovica Telesforo; David Lester; Paolo Girardi; Roberto Tatarelli; Paolo Martelletti
Journal:  Patient Relat Outcome Meas       Date:  2010-09-17

10.  Vagus nerve stimulation inhibits cortical spreading depression.

Authors:  Shih-Pin Chen; Ilknur Ay; Andreia Lopes de Morais; Tao Qin; Yi Zheng; Homa Sadeghian; Fumiaki Oka; Bruce Simon; Katharina Eikermann-Haerter; Cenk Ayata
Journal:  Pain       Date:  2016-04       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.